Background
==========

Ischaemic stroke results from obstruction of blood flow in a major cerebral vessel and leads to deregulation of genes whose expression promotes ischemic neuronal death and subsequent neurological dysfunction \[[@B1],[@B2]\]. Under ischemic conditions, energy metabolism fails, and severe reduction in mRNA and protein synthesis occurs in the ischemic core region. The tissue surrounding this area (peri-infarcted region) is able to maintain some functions, such as ionic homeostasis and can be partially salvaged by blood recirculation \[[@B3],[@B4]\].

The precise molecular mechanisms involved in ischemia-induced brain injury remain poorly understood. Limited knowledge of the molecular mechanisms involved in tissue regeneration has been gained from animal experiments using the middle cerebral artery occlusion (MCAO) model which replicates, in many aspects, the neuropathological changes following stroke in humans \[[@B5]\]. Although the contralateral side of the brain is not totally unaffected by ischemic damage, the collection of experimental and reference control tissue from the same animal is a better comparison than using sham-operated control in rats, while in human samples the only control tissue available is contralateral hemisphere. In addition, using contralateral tissue as a control and the direct comparison with stroke hemisphere provides the best model for validation as it removes inter-patient genetic variation and also minimises the differences in potential degradation between the target and reference mRNAs. This has been applied previously in both human \[[@B6],[@B7]\] and animal \[[@B8]-[@B10]\] studies. Rao et al. in particular observed very few differences in gene expression between sham and contralateral cortex at 24 h of reperfusion following MCAO in the rat \[[@B9]\].

Analysis of ischemic brain tissue with techniques capable of studying multiple transcripts simultaneously can identify gene expression changes previously not known to be implicated in ischemic pathophysiology and may lead to development of new targets for stroke therapy \[[@B11]\]. DNA microarray technology has been used to investigate the expression of thousands of genes in a single hybridization experiment. Several experimental studies have examined alteration of gene expression in the postischemic rat brain using microarray technology \[[@B8]-[@B10],[@B12]-[@B18]\], while blood genomic profiling in human stroke have been investigated in recent pilot studies \[[@B19],[@B20]\] (Table [1](#T1){ref-type="table"}). Critical comparison of gene expression profiles after stroke in humans with those in animal models may lead to a better understanding of the pathophysiology of brain ischaemia and allow an evaluation of the usefulness of animal models in stroke research.

###### 

Previous studies employing microarray approaches to study stroke

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            Soriano et al. 2000                       Jin et al. 2001                           Kim et al. 2002        Rao et al. 2002                                                               Schmidt-Kastner et al. 2002   Tang et al. 2002       Roth et al. 2003                                                             Kim et al. 2004                                                                    Lu et al. 2004         Moore et al. 2005                           Ford et al. 2006                     Tang et al. 2006                      Vikman and Edvinsson 2006                          Our data
  ------------------------- ----------------------------------------- ----------------------------------------- ---------------------- ----------------------------------------------------------------------------- ----------------------------- ---------------------- ---------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ---------------------- ------------------------------------------- ------------------------------------ ------------------------------------- -------------------------------------------------- ------------------------------------------------------------------------------------
  Material used             Rat brain tissue                          Rat brain tissue                          Rat brain tissue       Rat brain tissue                                                              Rat brain tissue              Rat brain tissue       Rat brain tissue                                                             Rat brain tissue                                                                   Rat brain tissue                                                   Rat brain tissue                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Model of ischemia         Permanent focal MCAO                      Transient global MCAO                     Permanent focal MCAO   Transient focal MCAO                                                          Transient focal MCAO          Permanent focal MCAO   Permanent focal MCAO                                                         Transient focal MCAO                                                               Transient focal MCAO   Blood from ischemic stroke patients         Permanent and transient focal MCAO   Blood from ischemic stroke patients   Post-mortem brain tissue from 11 stroke patients   Post-mortem brain tissue from 12 stroke patients and permanent focal rat MCAO

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  No of genes               750                                       374                                       1176                   1263                                                                          9044                          \~8,000                \~13,000                                                                     5,000                                                                              1,322                  \~19,000                                    8784                                 \~39,000                              7458                                               1176

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Time after ischemia       3 hours                                   4 hours\                                  6 hours                6 hours\                                                                      5 hours                       24 hours               1 hours\                                                                     3 hours\                                                                           30 min\                As soon as possible after hospitalization   24 hours                             3 hours\                              7--10 days (obtained 2--3 days post-mortem)        1 hour-21 days (rat) and 2--37 days (human, obtained by 6 hours post-mortem)
                                                                      24 hours\                                                        24 hours                                                                                                                           3 hours\                                                                     6 hours\                                                                           4 hours\                                                                                                5 hours\                                                                                 
                                                                      72 hours                                                                                                                                                                                            6 hours\                                                                     12 hours\                                                                          8 hours\                                                                                                24 hours                                                                                 
                                                                                                                                                                                                                                                                          24 hours                                                                     1 days\                                                                            24 hours\                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                       2 days\                                                                            3 days\                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                       4 days                                                                             7 days                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Cut-off values            2.0-fold                                  1.7-fold                                  2.0-fold               2.5-fold                                                                      1.7-fold                      2.0-fold               3.0-fold                                                                     2.0-fold                                                                           2.0-fold               \-                                          2.0-fold                             1.5-fold                              \-                                                 2.0-fold

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Confirmation of results   In situ hybridization, western blotting   Western blotting, immuno-histochemistry   RT-PCR                 Real-time PCR, antisense knockdown, western blotting, immuno-histochemistry   Microarray analysis only      Real-time RT-PCR       Cell culture, in situ hybridization, western blotting, immuno-fluorescence   Cell culture, northern blotting, RT-PCR, western blotting, immuno-histochemistry   Real-time RT-PCR       Real-time RT-PCR                            Microarray analysis only             Microarray analysis only              Real-time PCR, immuno-histochemistry               Cell culture, RT-PCR, western blotting, immuno-histochemistry, immuno-fluorescence

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Selected molecules        NGFI-C\                                   GRB2\                                     IFN-IP\                SOCS-3                                                                                                      NARP\                  PC4                                                                          FAK                                                                                Synaptic proteins      CD14\                                                                                                                  LY64\                                              PAK1\
                            ARC                                       SMN1                                      NDGAP-1\                                                                                                                           SPR\                                                                                                                                                                                                          CD36\                                                                                                                  ELK3\                                              MMP11\
                                                                                                                NPR                                                                                                                                SPIN2C\                                                                                                                                                                                                       FcGR2A\                                                                                                                POU3F4\                                            INI1
                                                                                                                                                                                                                                                   ARG1\                                                                                                                                                                                                         IFNGR1 caspase-1 a-catenin                                                                                             RHOA                                               
                                                                                                                                                                                                                                                   LBP                                                                                                                                                                                                                                                                                                                                                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Until recently, gene expression profiling had not been applied to patients dying of ischemic stroke, in part because human brain autopsies are not regularly obtained. Although tissue obtained from brain autopsies is generally of lower quality than that of brain biopsies obtained from living patients, the majority of RNA transcripts and proteins in the human brain are reasonably stable (compared to other tissues such as blood and kidney) and degrade to only a minor degree following death, thus making autopsy tissue a useful source for the isolation of nucleic acids and proteins \[[@B21]\]. Previous studies evaluating the mRNA quality in human post-mortem brain tissue have demonstrated a minimal effect upon their overall relative stability and indicated that frozen brains up to 72 hours post-mortem can be efficiently analyzed \[[@B22]\]. In line with that, in previous human brain studies, tissue was obtained up to a maximum of 6 hours \[[@B7]\], 40 hours \[[@B23]\], 45 hours \[[@B24]\] and 69 \[[@B6]\] hours following death. Moreover, after comparing mRNA levels in autopsies and biopsies, Castensson et al. \[[@B25]\] found a general similarity in the levels between the two groups, and suggested that mRNA levels in brain autopsy samples can provide clues about the brain in vivo. Interestingly, Almeida et al. \[[@B26]\] found that, even if performed on degraded RNA, RT-PCR can be used to provide a reliable estimate of in vivo mRNA levels, maybe due to the similarities in the rates of degradation between the target and reference mRNAs. Recently, Vikman and Edvinsson \[[@B27]\] investigated the gene expression in human brain after ischaemia using samples 7--10 days post-stroke; however, they obtained their samples after a considerable delay of 2--3 days post-mortem and they focused mainly on mRNA expression of receptors.

To identify the genes whose expression was changed in the human brain following ischaemia, we investigated the dynamic changes in gene expression in brain samples (collected within 6 h of death) from patients with various times of survival (2--37 days; Table [2](#T2){ref-type="table"}) following stroke and compared them with those at various time-points (1 hour -- 21 days) following middle cerebral artery occlusion (MCAO) in rats. The Atlas 1.2 cDNA microarray was used to screen for differential expression of 1176 genes and significantly de-regulated genes were selected through image analysis. We further investigated whether the altered mRNA and protein levels of a subset of deregulated molecules in the postischemic brain could be reproduced in an *in vitro*model of neuronal and endothelial cell culture under conditions of oxygen-glucose deprivation (OGD). The findings confirmed previous studies reporting that parallel screening of gene expression can detect both previously documented and novel transcriptional features of the cerebral response to ischemia, and demonstrated significant differences in gene expression between human stroke and the animal model.

###### 

Clinical Details of Patients

  Patient no.   Age/sex   Survival after stroke   NIHSS on admission   Hypertension^a^   Coronary artery disease   Atrial fibrillation   History of TIA/previous stroke   Hypercholesterolemia^b^   Smoking   Obesity^c^   Cause of death          Antiplatelets   Statins^d^   RSA-b^e^
  ------------- --------- ----------------------- -------------------- ----------------- ------------------------- --------------------- -------------------------------- ------------------------- --------- ------------ ----------------------- --------------- ------------ ----------
  1             63/F      2 days                  26                   Yes               No                        No                    No                               No                        No        No           Large ischemic stroke   No              No           Yes
  2             84/M      3 days                  21                   Yes               Yes                       No                    No                               No                        Yes       No           Malignant stroke        No              No           No
  3             68/M      3 days                  24                   Yes               Yes                       No                    No                               Yes                       No        No           Brain oedema            No              No           Yes
  4             84/M      6 days                  22                   Yes               Yes                       No                    No                               No                        No        No           Cardiac failure         Yes             Yes          No
  5             51/M      9 days                  25                   Yes               No                        No                    Yes                              No                        No        No           Respiratory infection   Yes             No           No
  6             74/M      15 days                 22                   Yes               Yes                       No                    No                               No                        No        Yes          Heart attack            Yes             No           Yes
  7             86/M      15 days                 14                   Yes               Yes                       No                    No                               Yes                       No        No           Urinary infection       Yes             No           No
  8             58/M      17 days                 16                   Yes               Yes                       No                    No                               Yes                       Yes       No           Cardiac infarction      Yes             No           No
  9             74/M      20 days                 12                   Yes               Yes                       No                    No                               No                        No        No           Bronchial aspiration    Yes             No           No
  10            73/M      26 days                 14                   Yes               Yes                       No                    No                               Yes                       No        Yes          Respiratory infection   Yes             No           Yes
  11            75/M      29 days                 20                   No                Yes                       Yes                   No                               No                        Yes       No           Septic shock            Yes             No           Yes
  12            60/F      37 days                 18                   Yes               Yes                       No                    No                               Yes                       Yes       No           Pulmonary embolism      Yes             No           No

^a^Blood pressure greater than 135/85 mmHg.

^b^Serum total cholesterol levels greater than 5.2 mmol.

^c^Body mass index greater than 30.

^d^Patients who were on statins before the ischemic stroke.

^e^Patients taking either angiotensin converting enzyme inhibitors or angiotensin type I receptor antagonists.

M = male; F = female; NIHSS = NIH Stroke Scale; TIA = Transient Ischaemic Attack.

Results
=======

cDNA microarray analysis
------------------------

The expression of ischemia-related genes was determined by comparing the infarct-induced expression (combined samples from infarcted and peri-infarcted areas) to that in the contralateral hemisphere: 77, 92 and 15 genes were de-regulated in stroke-affected regions in the 3 patient survival groups respectively, while 9, 51, 48, 166, 253, 117 and 261 genes were altered at the 7 different time-points in the animal model compared to the controls (Figure [1](#F1){ref-type="fig"}). The combined number of differentially expressed transcripts in stroke patients represented 6.5%, 7.8% and 1.3% respectively in each survival group of the total number of the genes on the microarray. These findings compare with 0.8%, 4.3%, 4%, 14.1%, 21.5%, 10% and 22.2% of genes respectively at each time-point in rats.

![**Statistical analysis of microarray data**. Total number of genes and number of overlapping genes (between the two array sets) deregulated following stroke in human and rat (A). Scatter plots representing the data dispersion over two logarithmic scales for all time-points in human (B) and rat (C).](1471-2202-8-93-1){#F1}

In total, 126 genes were deregulated after stroke in humans and 335 in the rat MCAO model. However, these data are not directly comparable since many transcripts in the human array were not present in the rat array and *vice versa*. Out of a total of 393 genes present in both arrays, 31, 49 and 5 showed deregulated expression in the 3 patient groups respectively, whilst 7, 27, 26, 62, 107, 34 and 107 genes were deregulated at each of the 7 time-points respectively following rat MCAO (Table [3](#T3){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). Of the 393 overlapping transcripts, the expression of 36 was changed only in the human study, compared with 184 that were altered only in the animal model, while only 41 deregulated genes were shared between the two studies. Interestingly, the mean fold changes in the human data were much higher than in the rat.

###### 

Genes deregulated in both human and animal stroke microarrays

                                                         Human                  Rat                Human              Rat                                                           
  ------------------------------------------------------ ---------------------- ------------------ ------------------ ------------------ ----------- ------------------ ----------- --------------
  c-jun proto-oncogene                                   [J04111](J04111)       [P05412](P05412)   [X17163](X17163)   [P17325](P17325)   4.4-fold    9 -- 20            3.5-fold    1 h -- 24 h
  Matrix metalloproteinase 11                            [X57766](X57766)       [P24347](P24347)   [U46034](U46034)   [P97568](P97568)   3.2-fold    2 -- 20            2.6-fold    3 days
  Calcium/calmodulin-dependent kinase (CAMK1)            [L41816](L41816)       [Q14012](Q14012)   [L24907](L24907)   [Q63450](Q63450)   17.2-fold   2 -- 20            0.05-fold   21 days
                                                                                                   [L26288](L26288)   [Q63084](Q63084)                                              
  LIM domain kinase 1                                    [D26309](D26309)       [P53667](P53667)   [D31873](D31873)   [P53669](P53669)   3.6-fold    2 -- 20            2.4-fold    3 days
                                                                                                                                                                        0.4-fold    21 days
  T-Lymphocyte maturation-associated protein             [M15800](M15800)       [P21145](P21145)   [U31367](U31367)   [Q64349](Q64349)   1.7-fold    2 -- 6             0.2-fold    21 days
  Retinoic Acid Receptor beta                            [M84820](M84820)       [P28702](P28702)   [M81766](M81766)   [P49743](P49743)   2.0-fold    2 -- 6             0.1-fold    21 days
                                                         S54072                 [P28703](P28703)                                                                                    
  Tyrosine Phosphatase 1B                                [M31724](M31724)       [P18031](P18031)   [M33962](M33962)   [P20417](P20417)   3.4-fold    2 -- 6             0.2-fold    21 days
  Adenosine A1 Receptor                                  [S56143](S56143)       [P30542](P30542)   [M64299](M64299)   [P25099](P25099)   2.6-fold    2 -- 6             5.2-fold    4 hrs
  Growth arrest & DNA damage-inducible 153               [S40706](S40706)       [P35638](P35638)   [U30186](U30186)   [Q62804](Q62804)   2.4-fold    2 -- 6             2.1-fold    3 days
                                                         [S62138](S62138)                                                                                                           
  Glutamate Decarboxylase 67                             [M81883](M81883)       [Q99259](Q99259)   [M34445](M34445)   [P18088](P18088)   5.6-fold    2 -- 6             2.5-fold    21 days
  Glutamate Decarboxylase 65                             [M81882](M81882)       [Q99259](Q99259)   [M72422](M72422)   [Q05683](Q05683)   22.7-fold   2 -- 20            2.2-fold    3 days
  Neurotrophin 3                                         [M37763](M37763)       [P20783](P20783)   [M34643](M34643)   [P18280](P18280)   5.1-fold    2 -- 37            2.2-fold    12 hrs
  Inhibitor of DNA binding 2                             [M97796](M97796)       [Q02363](Q02363)   [D10863](D10863)   [P41137](P41137)   5.6-fold    2 -- 20            0.4-fold    21 days
  Neuropeptide Y                                         [K01911](K01911)       [P01303](P01303)   [M20373](M20373)   [P07808](P07808)   8.8-fold    2 -- 20            0.04-fold   21 days
  Glia Maturation Factor beta                            [M86492](M86492)       [P17774](P17774)   [Z11558](Z11558)   [Q63228](Q63228)   7.6-fold    2 -- 6             0.04-fold   21 days
  High Mobility Group Protein 1                          [M23619](M23619)       [P17096](P17096)   [M64986](M64986)   [P27109](P27109)   4.3-fold    2 -- 37            3-fold      4 h -- 3 d
                                                                                                                      [P27428](P27428)                                  0.3-fold    21 days
  Early Growth Response Protein 1                        [X52541](X52541)       [P18146](P18146)   [M18416](M18416)   [P08154](P08154)   4.4-fold    2 -- 20            3.9-fold    1 h -- 12 h
                                                         [M62829](M62829)                          [J04154](J04154)                                                     0.2-fold    21 days
  TAT-Binding Protein 1                                  [M34079](M34079)       [P17980](P17980)   [U77918](U77918)   [P97638](P97638)   3.8-fold    2 -- 20            0.4-fold    21 days
  Glutathione S-Transferase 1                            [J03746](J03746)       [P10620](P10620)   [J03752](J03752)   [P08011](P08011)   17.5-fold   2 -- 20            10.8-fold   24 h -- 21 d
  Fibroblast Growth Factor Receptor 1                    [M63887](M63887)       [Q02063](Q02063)   [D12498](D12498)   [Q04589](Q04589)   10.1-fold   2 -- 20            4-fold      4 h -- 24 h
                                                         [M63888](M63888)       [Q02065](Q02065)                                                                                    
                                                         [M63889](M63889)                                                                                                           
  Interleukin 10                                         [M57627](M57627)       [P22301](P22301)   [L02926](L02926)   [P29456](P29456)   2.4-fold    2 -- 20 26 -- 37   6.4-fold    21 days
                                                                                                                      [Q63263](Q63263)   0.2-fold                                   
  Heat Shock Protein 27                                  [X54079](X54079)       [P04792](P04792)   [M86389](M86389)   [P42930](P42930)   0.6-fold    2 -- 20            15.2-fold   4 h -- 24 h
  Heat Shock Protein 70                                  [M11717](M11717)       [P08107](P08107)   [Z27118](Z27118)   [Q63718](Q63718)   0.6-fold    2 -- 6             9.4-fold    1 h -- 24 h
                                                                                [P19790](P19790)                                                                                    
  Thioredoxin Peroxidase 1                               [L19185](L19185)       [P32119](P32119)   [U06099](U06099)   [P35704](P35704)   4.9-fold    2 -- 20            3.9-fold    21 days
                                                         [X82321](X82321)       [P31945](P31945)                                                                                    
  Platelet-Derived Growth Factor A                       [X06374](X06374)       [P04085](P04085)   [L06894](L06894)   [P28576](P28576)   1.6-fold    2 -- 6             0.5-fold    21 days
  Matrix Metalloproteinase 14                            [X83535](X83535)       [Q92678](Q92678)   [X83537](X83537)   [Q10739](Q10739)   6.9-fold    2 -- 6             3.3-fold    24 h -- 3 d
  Kinase receptor TYRO3 Sky proto-oncogene               [D17517](D17517)       [Q06418](Q06418)   [D37880](D37880)   [P55146](P55146)   3.1-fold    9 -- 20            4.0-fold    24 h -- 3 d
                                                                                                                                                                        0.4-fold    21 days
  CSF-1-Receptor                                         [X03663](X03663)       [P07333](P07333)   [X61479](X61479)   [Q00495](Q00495)   89.2-fold   9 -- 20            2.8-fold    3 days
  Insulin-like Growth Factor Binding Protein 2           [M35410](M35410)       [P18065](P18065)   [J04486](J04486)   [P12843](P12843)   79.7-fold   9 -- 20            2.1-fold    3 days
  Mitogen activated kinase 1/2                           [M84489](M84489)       [P28482](P28482)   [M64300](M64300)   [P27703](P27703)   48.6-fold   9 -- 20            0.3-fold    21 days
  Aquaporin 4                                            [U34846](U34846)       [P55087](P55087)   [U14007](U14007)   [P47863](P47863)   18-fold     9 -- 20            3.2-fold    3 days
  erbB2 proto-oncogene Neu proto-oncogene                [M95667](M95667)       [P04626](P04626)   [X03362](X03362)   [P06494](P06494)   11.2-fold   9 -- 20            2.7-fold    12 hrs
                                                         [M11730](M11730)       [Q14256](Q14256)                                                                                    
  L-type calcium channel β3                              [U07139](U07139)       [P54284](P54284)   [M88751](M88751)   [P54287](P54287)   10.3-fold   9 -- 20            8.6-fold    21 days
  Ras-related protein RAB3A                              [M28210](M28210)       [P20336](P20336)   [X06889](X06889)   [P05713](P05713)   13.9-fold   9 -- 20            0.3-fold    21 days
  CAMK-II beta                                           [U50358](U50358)       [Q13554](Q13554)   [M16112](M16112)   [P08413](P08413)   1.8-fold    9 -- 20            0.3-fold    21 days
  Growth Factor Receptor-Bound 2                         [L29511](L29511)       [Q63057](Q63057)   [D49846](D49846)   [Q63057](Q63057)   19.9-fold   9 -- 20            2.7-fold    3 days
                                                         [M96995](M96995)       [Q14450](Q14450)                      [Q14450](Q14450)                                              
  Signal Transducer & Activator of Transcription 3       [L29277](L29277)       [P40763](P40763)   [X91810](X91810)   [P52631](P52631)   0.4-fold    9 -- 20            6.6-fold    4 h -- 3 d
                                                                                                                                                                        0.05-fold   21 days
  Neuronatin                                             [U25033](U25033)       [Q16517](Q16517)   [U08290](U08290)   [Q62649](Q62649)   11.1-fold   9 -- 20            0.4-fold    21 days
                                                                                                                      [Q62663](Q62663)                                              
  Glutathione S-Transferase P                            [X08058](X08058)       [P09211](P09211)   [X02904](X02904)   [P04906](P04906)   3.1-fold    9 -- 20            0.1-fold    1 hr
  Glucocorticoid-regulated serine/threonine kinase GSK   [AJ000512](AJ000512)   [O00141](O00141)   [L01624](L01624)   [Q06226](Q06226)   0.6-fold    26 -- 37           2.4-fold    3 days
                                                                                                                                                                        0.05-fold   21 days
  Glucose Transporter 1                                  [K03195](K03195)       [P11166](P11166)   [M13979](M13979)   [P11167](P11167)   0.6-fold    26 -- 37           11.6-fold   4 h -- 21 d

Amongst these genes we examined in more detail a small subset with no prior report of a role in stroke (PAK1, MMP11 and INI1). PAK1 was only induced in the human study although present in both microarray sets, MMP11 was induced in both cases, while INI1 was induced in the human but was not present in the rat microarray set. To confirm the microarray data, RT-PCR was carried out on selected deregulated genes. The temporal expression patterns of these genes following RT-PCR showed good agreement with the corresponding expression profiles obtained from the microarray analysis, supporting the validity of the data obtained from the microarrays. Using Western blotting and immunohistochemistry, PAK1, INI1 and MMP11 protein expression and localization was determined in the contralateral and ipsilateral brain areas of individual stroke patients and rats subjected to MCAO, and in HBMEC and HFN exposed to OGD and reperfusion.

Integrase Interactor 1 (INI1)
-----------------------------

In agreement with the microarray data, RT-PCR demonstrated an increase in *ini1*mRNA levels in peri-infarcted and infarcted areas of patients who survived between 2 and 6 days following stroke (Figure [2A](#F2){ref-type="fig"}). Analysis of INI1 protein expression in samples from individual stroke patients showed that protein levels were increased in peri-infarcted and infarcted regions in 8 of 12 samples (Table [4](#T4){ref-type="table"}; Figure [2Bi](#F2){ref-type="fig"} and [2Bii](#F2){ref-type="fig"}). Only one patient who survived for 3 days after stroke showed decreased protein expression. Cells from contralateral white matter were not stained for INI1 but some weak neuronal cytoplasmic staining was seen in grey matter (Figure [2Ci](#F2){ref-type="fig"}). An increase in its expression was observed in the cytoplasm of cells with the morphological appearance of glia and microvessels from peri-infarcted and infarcted areas of patients surviving for 3 to 29 days after stroke (Figure [2Cii](#F2){ref-type="fig"} and [2Ciii](#F2){ref-type="fig"}). In the rat, RT-PCR and Western blotting demonstrated no notable changes in INI1 mRNA and protein expression respectively following MCAO. Weak cytoplasmic staining was observed in contralateral neurons but no differences in the level of INI1 neuronal expression occurred following MCAO (data not included). Finally, HFN and HBMEC exposed to OGD and/or reperfusion showed no difference in mRNA and protein levels for INI1 when compared with untreated cells.

###### 

Protein expression in infarcted (I) and peri-infarcted (P) areas (Fold increase compared to contralateral hemisphere)

                          PAK1   INI1   MMP11               
  ------- --------------- ------ ------ ------- ----- ----- -----
  1       2               2.2    1.0    1.5     1.5   1.5   1.5
  2       3               3.3    4.0    0.2     0.4   1.0   1.0
  3       3               1.0    1.0    4.2     4.3   0.7   0.7
  4       6               1.0    1.0    4.3     5.8   1.6   1.5
  5       9               1.5    0.4    3.2     3.3   ND    ND
  6       15              2.3    1.5    2.8     1.0   1.7   1.6
  7       15              3.0    3.2    1.7     2.0   1.0   1.0
  8       17              1.0    1.0    1.0     1.0   1.0   1.0
  9       20              1.0    1.0    1.0     1.0   1.0   1.0
  10      26              1.5    1.5    1.0     1.6   5.1   2.2
  11      29              1.0    1.5    2.2     2.8   1.8   3.5
  12      37              1.5    1.0    1.7     1.7   1.0   1.5
  Total   Upregulated     7      5      8       8     5     6
          Downregulated   0      1      1       1     1     1
          No change       5      6      3       3     5     4
          No detection    0      0      0       0     1     1

![**INI1 expression in human brain following stroke**. RT-PCR demonstrated an increase in *ini1*mRNA levels in infarcted and peri-infarcted areas of pooled samples from patients surviving from 2 to 6 days following stroke (A). Western blotting showed an increase in protein levels in infarcted and peri-infarcted areas of patients surviving for 3 (Bi) and 6 (Bii) days following stroke. Moderate INI1 neuronal staining (arrow) in contralateral areas of a patient surviving for 3 days after stroke (Ci). Strong INI1 staining in cells (arrows) from infarcted areas of a patient surviving for 15 days after stroke (Cii and iii) (C: Contralateral, P: Peri-infarct, I: Infarct).](1471-2202-8-93-2){#F2}

Matrix Metalloproteinase 11 (MMP11)
-----------------------------------

For MMP11, RT-PCR data agreed with the findings from the microarray study, showing increased mRNA levels in infarcted and peri-infarcted tissue from patients surviving 2--20 days following stroke (Figure [3Ai](#F3){ref-type="fig"}). Western blotting in individual patient samples demonstrated that 6 of 12 patients had elevated MMP11 protein levels (Table [4](#T4){ref-type="table"}; Figure [3Bi](#F3){ref-type="fig"} and [3Bii](#F3){ref-type="fig"}). The majority of cells from contralateral grey and white matter were not stained for MMP11 (Figure [3Ci](#F3){ref-type="fig"}). In patients surviving from 3 days to 4 weeks, endothelial cells and neurons from both infarcted and peri-infarcted tissue were stained positive for MMP11 (Figure [3Cii](#F3){ref-type="fig"} and [3Ciii](#F3){ref-type="fig"}). In the rat model, RT-PCR confirmed the microarray data for some of the time-points, showing no notable change in mRNA levels at 1 and 12 h but a prolonged upregulation at 3 days following MCAO (Figure [3Aii](#F3){ref-type="fig"}). Protein levels were elevated at 1 h, 24 h and 3 days, after which they returned to control levels. No staining for MMP11 was seen in contralateral areas (Figure [3Di](#F3){ref-type="fig"}), but an increase in its expression occurred in neurons following MCAO, in particular at 12 and 24 h (Figure [3Dii](#F3){ref-type="fig"}). MMP11 mRNA and protein levels remained unchanged in HFN and HBMEC exposed to conditions of oxygen-glucose deprivation.

![**MMP11 expression in human and rat brain following stroke**. RT-PCR demonstrated an increase in MMP11 mRNA levels in infarcted and peri-infarcted areas of patients surviving from 2 to 6 days following stroke (Ai) and rats at 3 days after MCAO (Aii). Western blotting demonstrated an increase in protein levels in infarcted and peri-infarcted areas of patients surviving for 29 (Bi) and 26 (Bii) days following stroke. Weak MMP11 staining in cells from contralateral areas of a patient surviving for 5 days following stroke (Ci). Blood vessels (Cii) and neurons (Ciii) strongly stained for MMP11 in peri-infarcted areas of a patient surviving for 15 days after stroke (arrows). No MMP11 staining observed in contralateral hemisphere of rat brain at 1 h after MCAO (Di) but neurons from infarcted areas of rat brain were stained positive for MMP11 at 3 days following MCAO (Dii) (C: Contralateral, P: Peri-infarct, I: Infarct).](1471-2202-8-93-3){#F3}

P21-activated kinase 1 (PAK1)
-----------------------------

RT-PCR confirmed the upregulation of *pak1*determined by the microarrays in pooled samples from stroke patients who survived between 2 and 6 days following stroke (Figure [4A](#F4){ref-type="fig"}). Western blotting showed an upregulation in the protein levels of PAK1 in 6 of 12 patients (Table [4](#T4){ref-type="table"}; Figure [4Bi](#F4){ref-type="fig"} and [4Bii](#F4){ref-type="fig"}). No staining was seen in contralateral white matter, while, in grey matter, PAK1 stained weakly the cytoplasm of some neurons (Figure [4Di](#F4){ref-type="fig"}). In patients surviving for 3 days to 4 weeks after stroke, increased PAK1 nuclear staining was seen in neurons in both peri-infarcted and infarcted regions (Figure [4Dii](#F4){ref-type="fig"}). In the rat, RT-PCR showed no significant changes in the mRNA levels for *pak1*at most of the time-points examined. However, Western blotting showed an upregulation in protein levels 1, 12 and 24 h after MCAO, returning to control levels at 3 days, and becoming downregulated at 7 days following MCAO (Figure [4Ci](#F4){ref-type="fig"} and [4Cii](#F4){ref-type="fig"}). Weak staining was observed in neurons from the contralateral hemisphere (Figure [4Ei](#F4){ref-type="fig"}), but an increase in cytoplasmic and nuclear staining in neurons occurred following MCAO, in particular at 1 h and 24 h (Figure [4Eii](#F4){ref-type="fig"}). Finally, an increase in PAK1 expression was also seen in human foetal neurons following oxygen-glucose deprivation (Figure [4Fi](#F4){ref-type="fig"} and [4Fii](#F4){ref-type="fig"}).

![**PAK1 expression in human and rat brain following stroke**. RT-PCR demonstrated an increase in PAK1 mRNA in infarcted and peri-infarcted areas of pooled samples from patients surviving from 2 to 6 days following stroke (A). Western blotting demonstrated an increase in protein levels in infarcted and peri-infarcted areas of patients surviving for 3 (Bi) and 15 (Bii) days following stroke and in rats at 12 h (Ci) and 24 h (Cii) following MCAO. Weak neuronal (axonal) staining (arrow) observed in contralateral areas of a patient surviving for 15 days following stroke (Di). Strong PAK1 staining in neurons (arrow) and cells with the morphological appearance of glia from infarcted areas of a patient surviving for 3 days following stroke (Dii). No staining observed in contralateral areas of rat brain at 24 h following MCAO (Ei) while strong PAK1 staining was seen in neurons (arrow) and cells with the morphological appearance of glia from infarcted areas of rat brain 1 h following MCAO (Eii). Stronger PAK1 immunofluorescent staining was seen in HFN following OGD (Fii) compared to control (Fi) (C: Contralateral, P: Peri-infarct, I: Infarct).](1471-2202-8-93-4){#F4}

Discussion and Conclusion
=========================

In the human brain, many differentially expressed genes were observed from 2 to 6 days and from 9 to 20 days after stroke, with the majority being upregulated. The number of deregulated genes declined during 26 to 37 days after stroke, indicating that dynamic changes in gene expression occur during the first days to few weeks in the human postischaemic brain. In the rat brain, few differences were observed at 1 hour, while the number of differentially expressed genes steadily increased with time after MCAO, with a peak after 3 days, supporting the concept of active mechanisms initiated during the acute phase after experimental stroke and lasting for several days. The number of upregulated genes gradually increased, peaking at 3 days, while downregulated genes were detected 24 h after MCAO and increased dramatically until the final measured time-point at 21 days (Figure [1](#F1){ref-type="fig"}).

The limitations of post-mortem brain samples in cDNA microarray analysis concern the small sample size and potential low quality and the genetic heterogeneity and diversity in terms of age, sex and previous medical history within a group of patients \[[@B28],[@B29]\]. We found that analysis of postischaemic gene expression using a cDNA microarray can allow identification of known and novel transcriptional events, molecular participants and signalling mechanisms in cerebral ischaemia as previously suggested, but can also detect differences in gene expression between distinct organisms.

The present gene expression profile study is the first large-scale microarray report showing altered expression of several genes following human stroke. These included genes participating in transcription, apoptosis, inflammation and neuroprotection. Many genes/proteins previously shown to be deregulated following stroke were reported in our study too e.g. IL-10 \[[@B30],[@B31]\], PDGF \[[@B32]\], STAT3 \[[@B33],[@B34]\], MAPK1/2 \[[@B35]\]. To test whether our microarray analysis could predict novel candidate genes involved in the cerebral response to ischaemia with possible functional importance and significance in stroke-induced neuronal damage, we measured protein expression and cellular localisation for three induced genes, INI1, PAK1 and MMP11. They were chosen because they showed at least 2-fold mRNA induction and there was no prior published evidence implicating them in human cerebral ischaemia.

PAK1 is a downstream Rac effector and a major cyclin-dependent kinase 5 (Cdk5) substrate and target that co-localizes with p35/Cdk5 at neuronal peripheries. P35/Cdk5 causes PAK1 hyperphosphorylation, which results in PAK1 down-regulation and is likely to have an impact on the dynamics of the reorganization of the actin cytoskeleton in neurons during dendrite development \[[@B36]\]. Based on this evidence, these authors proposed the existence of a neuron-specific signalling complex involving Cdk5/p35-PAK1 that inhibits PAK1 activity in neurons. We have recently provided evidence for a potential role of Cdk5/p35 in the response to ischaemic injury as we showed association of Cdk5 with nuclear damage, by demonstrating co-expression of Cdk5 in TUNEL-positive neurons following human stroke and in propidium iodide-positive human foetal neurons following OGD \[[@B37]\]. Here, we have reported for the first time an upregulation in PAK1 protein levels in human and rat brain samples following MCAO and in HFN following oxygen-glucose deprivation. Although in the animal model PAK1 protein levels returned to normal 3 days following stroke, some patients showed elevated levels for PAK1 at later time-points too. In both human and the animal model, neurons were the predominant type of cells stained positive for PAK1.

MMP11 or stromelysin-3 (ST3), first isolated as a breast cancer-associated protease, is not expressed in the majority of normal adult organs but is expressed during a number of pathological processes, including wound healing and atherosclerotic lesions \[[@B38],[@B39]\]. Although other metalloproteinases have been studied extensively following stroke \[[@B40],[@B41]\], there is no report of the expression of MMP11 following stroke *in vivo*or *in vitro*. Here we report an increase in protein levels of MMP11 following stroke in both human and rat brain, although the increase seen in man remained elevated much longer. Although MMP11 shares many similarities with other MMPs, it also differs in that it exhibits anti-apoptotic properties, a first-known activity for a MMP \[[@B42]\]. Moreover, although it is expressed in many processes involving tissue remodelling, cell migration and cell death, the pathways through which it participates in pathogenesis remain unclear, largely due to the lack of information on its substrates *in vivo*\[[@B43]\].

INI1 is a tumour suppressor gene, thought to exert its tumour suppressor function by mediating cell cycle arrest \[[@B44]\]. It was initially identified as a human homolog of yeast transcriptional activator SNF5 that binds to the HIV-1 integrase and stimulates its DNA-joining activity \[[@B45]\]. Brains of AIDS patients had been shown to manifest neuronal injury and apoptotic-like cell death raising the question about the way HIV-1 resulted in neuronal damage, since neurons themselves are very rarely infected by the virus \[[@B46]\]. Adler *et al*. \[[@B47]\] also reported an association of the human SNF5/INI1 protein with growth arrest and DNA damage-inducible protein 34 (GADD34) that mediates growth arrest and apoptosis in response to stress signals \[[@B48],[@B49]\]. Our study is the first to suggest a potential role for INI1 in pathways activated after stroke with a possible role in brain injury. However, in the animal model study, INI1 levels remained unchanged following stroke. The reason for this discrepancy warrants further studies.

Many experimental trials of stroke therapies have failed to translate to human clinical trials and one possible way to improve the success rate can be through comparative genomics. As it has been recently commented, it is very surprising that the exciting developments observed in basic and clinical stroke research over the past two decades have occurred in parallel, with too little direct translation between bench and bedside \[[@B50]\]. Here, we have provided substantial evidence that, although the available animal models of MCAO may well be suitable to study the pathophysiological changes following the occlusion of a cerebral vessel, they may not entirely reflect the pathophysiological process through which stroke evolves in humans. The species difference is one of the main reasons accounting for the lack of success of bench to bedside translation in the stroke area. Limitations of our study include the fact that early acute phase changes in gene expression may have been missed since genes induced and returning to normal during the first 48 hours post-ischaemia in man could not have been detected. Moreover, since we analyzed pooled RNA samples, small changes in gene expression occurring in a minority of the samples may have been missed. However, there was only a small overlap of our results with prior studies in experimental stroke involving brain tissue, and the successful identification of novel ischaemia-related genes reported here suggests that performing a further study using whole genome microarrays would be valuable.

Methods
=======

Human brain autopsy specimens
-----------------------------

Human brain tissue samples were obtained from 12 patients who died from acute ischaemic stroke, with the approval of the local Ethics Committee and Brain Bank at the Department of Neuropathology, Collegium Medicum, Jagiellonian University, Krakow, Poland. All patients were admitted with large middle cerebral artery strokes confirmed by CT-scan or MRI. The patients, 10 male and 2 female, were aged between 51 and 86 years and had survived between 2--37 days following ischaemic stroke (Table [2](#T2){ref-type="table"}). Routine blood parameters were determined on admission. Full clinical examinations, including NIH Stroke Scale, were also carried out on admission. Excluded from the study were patients with recent history of head trauma, major cardiac, renal, hepatic or cancerous disease and obvious signs of infection after admission. Immediately after death the body was put in a cold chamber and tissue was collected within 6 h of death. Tissue samples were taken from infarct and peri-infarcted zones while controls were obtained from the contralateral hemisphere at the same time. The peri-infarcted areas were defined in tissue sections as the tissue immediately surrounding the infarcted core which contained some necrotic cells and showed evidence of tissue disorganisation confirmed by histology. Sections were stained with 2,3,5-triphenyltetrazolium chloride which stains active mitochondria pink; therefore, non stained areas represented stroke affected cortical regions (data not included). Tissue specimens were immediately frozen in liquid nitrogen, kept at -70°C and a portion of each sample was processed for histology and stained with haematoxylin and eosin to determine tissue morphology \[[@B51]\].

Rat middle cerebral artery occlusion
------------------------------------

Stroke experiments were performed on female Sprague-Dawley rats (weight: 230--270 g) as they suffer less than male during ischaemia. Cerebral ischaemia was produced using a modified method of Baron \[[@B52]\] by distal, permanent occlusion of the MCA by electrocautery as described elsewhere \[[@B53],[@B54]\]. The mortality in this model is very low. Sets of six animals (3 for morphological studies and 3 pooled together) for each time-point were sacrificed at 1 h, 4 h, 12 h, 24 h and 3, 7 and 21 days.

In vitro oxygen-glucose deprivation (OGD)
-----------------------------------------

Human brain microvascular endothelial cells (HBMEC) were obtained from TCS CellWorks (Buckingham, UK) and cultured according to the supplier\'s instructions. Human foetal (cerebral cortical) neurons (HFN) were extracted and cultured with permission from the Local Ethics Committee. Brain tissue from foetus specimens of 14--19 weeks gestational age, legally aborted and with the appropriate written consent, were collected in cold preservation medium and cells were isolated and cultured as described elsewhere \[[@B55]\]. For OGD experiments, the culture medium was replaced by glucose-free medium containing 2% foetal bovine serum (TCS CellWorks, Buckingham, UK) and cells were cultured at 37°C in a humidified chamber with 94% N~2~, 1% O~2~, and 5% CO~2~for 6 h (HBMEC) or 95% N~2~and 5% CO~2~for 14 h (HFN) followed by 24 h reperfusion in fresh medium containing 4.5 g/l glucose. This resulted in approximately 30% of cells undergoing apoptosis after OGD and 60% following reoxygenation, as determined from our pilot studies. Cells cultured in normoxic conditions without glucose deprivation were used as controls. In some experiments, propidium iodide (10 μg/ml) was added to the cultures 1 h before the end of the experiment to stain dead and dying cells.

cDNA microarrays
----------------

We established mRNA expression profiles of the damaged brain tissues between 2 to 6 days, 9 to 20 days, and 26 to 37 days after stroke in human patients and 1, 4, 12, 24 hours and 3, 7 and 21 days after the ischaemic insult in rats. The corresponding samples from the non-ischemic control hemisphere were used to measure the normal mRNA abundance of the modulated genes in each tissue at each time point. RNA from three stroke patients was pooled for each patient survival group while RNA from three MCAO rats was also pooled at each time-point to improve yields in preparation of poly A^+^RNA. Although pooling was previously thought to affect data quality, Kendziorski *et al.*\[[@B56]\] have recently shown that inference was not adversely affected by pooling. The different patient groups were selected to match the three physiological stages following stroke i.e. the inflammatory (lasting up to a maximum of 5--6 days), the proliferative (lasting up to three weeks following stroke) and the remodelling/maturation (starting during the third or fourth week).

RNA was extracted according to the manufacturer\'s protocols (BD Biosciences, Oxfordshire, UK) and its quality was measured spectrophotometically. The protocol recommended by Clontech in their Atlas 1.2 microarray kit was used without any modification. Briefly, RNA was reverse-transcribed to cDNA, ^32^P-labelled and applied to the array for overnight hybridisation at 68°C. Following washing, the array was exposed to a phosphorimaging plate for 12--72 hours and data analysis was performed using the AtlasImage 1.5 software. The results were normalized using two housekeeping genes, ubiquitin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). As in the majority of microarray studies mentioned before, only those genes upregulated \> 2-fold or downregulated \< 0.5-fold were counted as deregulated and taken into consideration. The microarray data are available in Gene Expression Omnibus under the accession number GSE9391.

Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
--------------------------------------------------------

Gene expression was examined by semi-quantitative RT-PCR with standard reaction conditions of a 10 min denaturation at 94°C, followed by 35 cycles of 1 min at 94°C, 1 min at primer-specific annealing temperatures (Table [5](#T5){ref-type="table"}) and 1 min at 72°C and a final 10 min extension step at 72°C. Samples without cDNA were used as negative controls and the products were visualized by agarose gel electrophoresis (1.5% w/v) and DNA stained with ethidium bromide (10 mg/ml). All experiments were carried out at 25, 30, 35 and 40 cycles to ensure the semi-quantitative nature of the results. The results were normalized using housekeeping gene GAPDH and semi-quantitavely analyzed using Scion Imaging Software version 4.02 (Scion Corporation, Maryland, USA). Sense and antisense oligonucleotide primers containing 18--27 nucleotides based on previously reported mRNA sequences in the GenBank depository were designed with the aid of the Primer3 Output Program (Version 0.2). InVitrogen plc. (Paisley, UK) synthesized the primer sets (Table [5](#T5){ref-type="table"}).

###### 

Primer sequences

  **Gene**   **Species**   **Primer Sequence**                        **T annealing**
  ---------- ------------- ------------------------------------------ -----------------
  *mmp11*    Human         5\'-TAAAGGTATGGAGCGATGTGAC-3\' (forward)   58°C
  *mmp11*                  5\'-TGGGTAGCGAAAGGTGTAGAAG-3\' (reverse)   
  *mmp11*    Rat           5\'-GATGGAGGCCAGCTAGTCAG-3\' (forward)     60°C
  *mmp11*                  5\'-ATGGTACATGACCACGCAGA-3\' (reverse)     
  *ini1*     Human         5\'-ACCCTGTCCAACAGCTCCCA-3\' (forward)     64°C
  *ini1*                   5\'-GGCCCAATCTTCTGAGATGC-3\' (reverse)     
  *ini1*     Rat           5\'-CCTGGGGCTCCTATACAAAA-3\' (forward)     60°C
  *ini1*                   5\'-CCATGACCGAGCAAATGAC-3\' (reverse)      
  *pak1*     Human         5\'-GCTGTTCTGGATGTGTTGGA-3\' (forward)     60°C
  *pak1*                   5\'-TCTGCTCTGGGGTTATCTGTG-3\' (reverse)    
  *pak1*     Rat           5\'-AGCAAAAGAGGCAACCAAGA-3\' (forward)     60°C
  *pak1*                   5\'-GGGTAAGGAATGGGATGGTT-3\' (reverse)     
  *gapdh*    Human         5\'-ATGATCTTGAGGCTGTTG-3\' (forward)       58°C
  *gapdh*                  5\'-CTCAGACACCATGGGGAA-3\' (reverse)       

Protein extraction and Western blotting
---------------------------------------

Proteins were extracted from tissues and the protein concentration of each sample was determined using the BioRad assay. For Western blotting, 10 μg of protein were separated by SDS-PAGE (13% w/v) and the proteins were electro-blotted onto nitrocellulose filters as described previously \[[@B57]\]. Filters were blocked in 1% w/v bovine serum albumin (BSA) in Tris-buffered saline Tween (TBS Tween) and stained overnight at 4°C with antibodies to the following proteins (obtained from Autogen Bioclear, Wiltshire, UK, unless stated otherwise) diluted in 1% BSA: MMP11 (CalBiochem; 1:500), PAK1 (1:500), INI1 (1:500), and α-actin (Sigma, 1:1000) used as a loading control. Membranes were washed in TBS-Tween before staining with the appropriate peroxidase-conjugated secondary antibody, diluted 1:1000 in 5% w/v milk in TBS-Tween for l h. Blots were developed with the ECL detection system (Amersham, UK). The relative intensities of the bands were measured in an LKB densitometer. Results are semi-quantitative and are given as a numerical (fold) change compared to the control (contralateral tissue) which was given an arbitrary value of 1.0. All experiments were performed twice and a representative example of patient(s) showing an increase in protein expression is given.

Immunohistochemistry/Immunofluorescence
---------------------------------------

Paraffin-embedded tissue samples were processed and serial 5 μm sections were cut. The Avidin-Biotin Peroxidase (ABC Vectastain kit, Vector Laboratories, Peterborough, UK) method was used and antibodies to MMP11, PAK1 and INI1 were used at a dilution of 1:50. Paraffin-embedded sections were deparaffinized, rehydrated and boiled for 10 min in an antigen unmasking solution of concentrated citric acid pH 6.0 as described elsewhere \[[@B57]\]. Slides were incubated in 0.5% v/v H~2~O~2~in methanol for 30 min, with normal serum for 20 min and then with a primary antibody (diluted in normal serum) for 30 min, followed by 30-min incubation with biotinylated secondary antibody (diluted 1:50) and finally with ABC complex (diluted 1:50) for 30 min at RT. Staining was completed after incubation with DAB substrate chromogen solution for 3--10 min. Slides were counterstained with haematoxylin, dehydrated, cleared and mounted in DPX. For immunofluorescence, cultured cells were fixed in 4% paraformaldehyde for 20 min, permeabilized with 0.2% Triton ×100 for 10 min, blocked with normal serum and stained with the primary antibody as above, followed by 1 h incubation with Alexa-fluor conjugated dye at RT. Negative control slides were performed in parallel, where primary antibody was replaced with washing buffer and processed as above (data not included).
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GAPDH: glyceraldehyde 3-phosphate dehydrogenase; HBMEC: human brain microvascular endothelial cells; HFN: human foetal neurons; INI1: integrase interactor 1; MCAO: middle cerebral artery occlusion; MMP11: matrix metalloproteinase; OGD: oxygen-glucose deprivation; PAK1: p21-activated kinase 1.
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